Trials
1 active
1 in total · 1 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “THT140 is a highly selective, orally- and intravenously- available, ATP-competitive inhibitor of PLK1.”In the company’s words, NCT05358379 on ClinicalTrials.gov
- Tested for
- Solid Tumor, Adult Lymphoma
- Main trialPhase 1/2
- “This is a 2-part, phase 1/2, open-label, multicenter study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, pharmacogenomics, and efficacy of THT40 administered orally daily. This study consists of Phase 1 and Phase 2 components in subjects with advanced solid tumors and lymphoma with a focus on tumors with ARID1A and similar mutations who have progressed despite having received standard therapy or for whom no standard therapy exists.”In the company’s words, NCT05358379 on ClinicalTrials.gov
- Other names
- Plogosertib
Other drugs for Solid Tumor, Adult Lymphoma
- GlofitamabRoche · Phase 3
- ObinutuzumabRoche · Phase 3
- TocilizumabRoche · Phase 3
- IbrutinibJohnson & Johnson (Janssen) · Phase 3
- SelinexorKaryopharm Therapeutics Inc · Phase 2/3
- XNW5004Evopoint Biosciences Inc. · Phase 3
Coming up1
- Nov 2028Phase 1/2 trial completes · ClinicalTrials.gov
Changes2
Last 90 days- 20 NovStatus changed: Unknown to Recruiting · ClinicalTrials.gov NCT05358379
- 20 NovCompletion date moved: 2025-08 to 2028-11 · ClinicalTrials.gov NCT05358379
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Recruiting | Nov 2028 | A Study to Investigate THT140, in Subjects With Advanced Solid Tumors and Lymphoma |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026